PROL4提高肺癌细胞LTEP-a-2对化疗药物顺铂的敏感性

PROL4 Elevates The Sensitivity of Lung CancerCell LTEP-a-2 to Cisplatin Treatment

PROL4(proline-rich protein 4)是我们筛选发现的一个在肺癌细胞中表达缺失的基因.为了深入研究其在肺癌中的生物学功能,构建了PROL4表达质粒,转染肺腺癌LTEP-a-2细胞,获得了稳定表达PROL4的单克隆细胞株.与空载对照细胞相比,过表达PROL4的LTEP-a-2细胞其生长的血清依赖性明显提高,软琼脂集落形成能力降低,裸鼠皮下荷瘤生长受到明显抑制.进一步研究发现,过表达PROL4可明显提高多种肺癌细胞对顺铂的敏感性,而且这种敏感性的提高与PROL4协同顺铂促进细胞凋亡密切相关.该研究结果为临床上如何提高肺癌的化疗效果提供了重要的实验依据.

PROL4 （proline-rich protein 4） was screened out in lung cancer cells for its defective expression in our previous study. By transfection of PROL4 into lung adenocarcinoma cell line LTEP-a-2, a stable cell strain was acquired. It was shown that in PROL4 expressing cells, compared to the vector control cells, the serum dependence of cell growth was markedly enhanced, soft agar colony-forming ability was suppressed. The tumor growth was also significantly restrained by PROL4 in vivo experiments. Furthermore, PROL4 transfected cancer cell strains were found to display an elevated sensitivity to cisplatin treatment than mock-transfectant control cells, and the sensitivity up-regulation was closely related to the rate of cell apoptosis induced by PROL4 and cisplatin cooperately. These results suggest that PROL4 is potentially a new genetic engineering target to enhance the chemotherapeutic effects of cisplatin in lung cancer treatment.